Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities

被引:100
作者
Haviv, F [1 ]
Bradley, MF
Kalvin, DM
Schneider, AJ
Davidson, DJ
Majest, SM
McKay, LM
Haskell, CJ
Bell, RL
Nguyen, B
Marsh, KC
Surber, BW
Uchic, JT
Ferrero, J
Wang, YC
Leal, J
Record, RD
Hodde, J
Badylak, SF
Lesniewski, RR
Henkin, J
机构
[1] Purdue Univ, Dept Biochem Engn, W Lafayette, IN 47907 USA
[2] Abbott Labs, Global Pharmaceut Res, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Dev Org, Abbott Pk, IL 60064 USA
关键词
D O I
10.1021/jm0401560
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The heptapeptide 1, NAc-Gly-Val-DIle-Thr-Arg-Ile-ArgNHEt, a structurally modified fragment derived from the second type-1 repeat of thrombospondin-1 (TSP-1), is known to possess antiangiogenic activity. However, therapeutic utility could not be demonstrated because this peptide has a very short half-life in rodents. To optimize the PD/PK profile of 1, we initiated a systematic SAR study. The initial structural modifications were performed at positions 5 and 7 of peptide 1 and at the N- and C-termini. Out of several hundred peptides synthesized, the nonapeptide 5 (ABT-526) emerged as a promising lead. ABT-526 inhibited VEGF-induced HMVEC cell migration and tube formation in the nanomolar range and increased apoptosis of HUAEC cells. ABT-526 showed acceptable PK in rodents, dog, and monkey. ABT-526, when incorporated in an angiogenic pellet implanted in the rat cornea at 10 mu M, reduced neovascularization by 92%. Substitution of DalloIle in place of DIle in ABT-526 provided nonapeptide 6 (ABT-510), which was 30-fold less active than ABT-526 in the EC migration but 20-fold more active in the tube formation assay. In comparison to ABT-526, ABT-510 has increased water solubility and slower clearance in dog and monkey. Radiolabeled ABT-510 demonstrated saturable binding to HMVEC cells at 0.02-20 nM concentrations and was displaceable by TSP-1. ABT-510 and ABT-526 were shown to significantly increase apoptosis of HUAEC cells. ABT-510 was effective in blocking neovascularization in the mouse Matrigel plug model and inhibited tumor growth in the mouse Lewis lung carcinoma model. Previous studies had shown that ABT-510 was effective in inhibiting the outgrowth of murine melanoma metastases in syngeneic mice and in blocking the growth of human bladder carcinoma implanted in nude mice. It had been also shown that ABT-510 could regress tumor lesions in pet dogs or cause unexpected stabilization of the disease in advanced canine cancer. ABT-526 and ABT-510 are the first compounds in the class of potent inhibitors of angiogenesis that mimic the antiangiogenic function of TSP-1. ABT-510 is currently in phase II clinical studies.
引用
收藏
页码:2838 / 2846
页数:9
相关论文
共 27 条
[1]  
[Anonymous], 1995, The molecular basis of cancer
[2]   APOPTOSIS AND NECROSIS - 2 DISTINCT EVENTS INDUCED, RESPECTIVELY, BY MILD AND INTENSE INSULTS WITH N-METHYL-D-ASPARTATE OR NITRIC-OXIDE SUPEROXIDE IN CORTICAL CELL-CULTURES [J].
BONFOCO, E ;
KRAINC, D ;
ANKARCRONA, M ;
NICOTERA, P ;
LIPTON, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) :7162-7166
[3]   How tumors become angiogenic [J].
Bouck, N ;
Stellmach, V ;
Hsu, SC .
ADVANCES IN CANCER RESEARCH, VOL 69, 1996, 69 :135-174
[4]  
Campbell SC, 1998, CANCER RES, V58, P1298
[5]   Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat [J].
Dawson, DW ;
Volpert, OV ;
Pearce, SFA ;
Schneider, AJ ;
Silverstein, RL ;
Henkin, J ;
Bouck, NP .
MOLECULAR PHARMACOLOGY, 1999, 55 (02) :332-338
[6]  
DEVOS, 2004, 40 ANN M ASCO NEW OR
[7]  
DIPIETRO LA, 1997, REGULATION ANGIOGENE, P295
[8]   Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a) [J].
Dudani, AK ;
Ganz, PR .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (01) :168-178
[9]   Seminars in medicine of the Beth Israel Hospital, Boston - Clinical applications of research on angiogenesis [J].
Folkman, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (26) :1757-1763
[10]  
FOURNIER GA, 1981, INVEST OPHTH VIS SCI, V21, P351